DMEM, high glucose, pyruvate
DMEM, high glucose, pyruvate
Actual product may vary
DMEM, high glucose, pyruvate
DMEM, high glucose, pyruvate
DMEM, high glucose, pyruvate
Gibco™

DMEM, high glucose, pyruvate

DMEM (Dulbecco's Modified Eagle Medium) is a widely used basal medium for supporting the growth of many different mammalian cells.Read more
Have Questions?
Change viewbuttonViewtableView
Catalog NumberQuantity
41966029
also known as 41966-029
500 mL
11995065500 mL
1199507310 x 500 mL
119950401000 mL
4196616110 L
41966052
also known as 41966-052
10 x 500 mL
Catalog number 41966029
also known as 41966-029
Price (EUR)
18,65
Online Exclusive
25,27
Save 6,62 (26%)
Each
Add to cart
Quantity:
500 mL
Customize this product
Price (EUR)
18,65
Online Exclusive
25,27
Save 6,62 (26%)
Each
Add to cart

DMEM (Dulbecco's Modified Eagle Medium) is a widely used basal medium for supporting the growth of many different mammalian cells. Cells successfully cultured in DMEM include primary fibroblasts, neurons, glial cells, HUVECs, and smooth muscle cells, as well as cell lines such as HeLa, 293, Cos-7, and PC-12. We offer a variety of DMEM modifications for a range of cell culture applications. Find the right formulation using the media selector tool.

This DMEM is modified as follows:

With: High Glucose, L-glutamine, Phenol Red, Sodium pyruvate

Without: HEPES

The complete formulation is available.

Using DMEM

DMEM is unique from other media as it contains 4 times the concentration of amino acids and vitamins than the original Eagle's Minimal Essential Medium. DMEM was originally formulated with low glucose (1 g/L) and sodium pyruvate, but is often used with higher glucose levels, with or without sodium pyruvate. DMEM contains no proteins, lipids, or growth factors. Therefore, DMEM requires supplementation, commonly with 10% Fetal Bovine Serum (FBS). DMEM uses a sodium bicarbonate buffer system (3.7 g/L), and therefore requires a 5–10% CO2 environment to maintain physiological pH.

For Research Use or Further Manufacturing. Not for diagnostic use or direct administration into humans or animals.
Specifications
Cell LineHeLa, 293, Cos-7, and PC-12
Cell TypePrimary Fibroblasts, Neurons, Glial Cells, HUVECs, Smooth Muscle Cells
Concentration1 X
Manufacturing QualitycGMP-compliant under the ISO 13485 standard
Product LineGibco
Product TypeDulbecco's Modified Eagle Medium (DMEM)
Quantity500 mL
Shelf Life12 Months
Shipping ConditionAmbient
ClassificationAnimal Origin-free
Culture TypeMammalian Cell Culture
FormLiquid
SterilitySterile-filtered
Sterilization MethodSterile-filtered
With AdditivesHigh Glucose, Glutamine, Phenol Red, Sodium Pyruvate
Without AdditivesNo HEPES
Unit SizeEach
Contents & Storage
Storage conditions: 2-8° C. Protect from light
Shipping conditions: Ambient
Shelf life: 12 months from date of manufacture

Frequently asked questions (FAQs)

What is the difference between DMEM, high glucose, pyruvate Cat. No. 41966029 and Cat. No. 11995065?

Cat. No. 41966029 is manufactured in the Paisley, Scotland facility, while Cat. No. 11995065 is dual manufactured in Grand Island, New York and Paisley, Scotland. Although the formulation is said to be equivalent for molarities, the components may differ (e.g., it could be that one used L-Cystine 2HCl the other L-Cystine). This should not affect performance. Both facilities are FDA-registered and ISO 13485 certified.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

What is the manganese concentration in DMEM? Do you offer manganese-free DMEM?

Manganese is not present in the formulation of our catalog DMEM media products.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

Citations & References (2)

Citations & References
Abstract
Agonism and antagonism at the insulin receptor.
Authors:Knudsen L, Hansen BF, Jensen P, Pedersen TÅ, Vestergaard K, Schäffer L, Blagoev B, Oleksiewicz MB, Kiselyov VV, De Meyts P,
Journal:PLoS One
PubMed ID:23300584
'Insulin can trigger metabolic as well as mitogenic effects, the latter being pharmaceutically undesirable. An understanding of the structure/function relationships between insulin receptor (IR) binding and mitogenic/metabolic signalling would greatly facilitate the preclinical development of new insulin analogues. The occurrence of ligand agonism and antagonism is well described for G ... More
Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.
Authors:Jones JL, Anderson JM, Phuah CL, Fox EJ, Selmaj K, Margolin D, Lake SL, Palmer J, Thompson SJ, Wilkins A, Webber DJ, Compston DA, Coles AJ
Journal:Brain
PubMed ID:20659956
Treatment of early relapsing-remitting multiple sclerosis with the lymphocyte-depleting humanized monoclonal antibody alemtuzumab (Campath [registered trade mark]) significantly reduced the risk of relapse and accumulation of disability compared with interferon ß-1a in a phase 2 trial [Coles et al., (Alemtuzumab vs. interferon ß-1a in early multiple sclerosis. N Engl J ... More